Raphael Landovitz, MD, on the Safety & Efficacy of PrEP Containing Long-Acting Cabotegravir
In this podcast, Dr Landovitz discusses the findings from his recent trial, HPTN 083, which indicates that long-acting cabotegravir injected once every 8 weeks is superior to daily oral TDF/FTC in the prevention of HIV among cisgender men and transgender women who have sex with men. These findings were presented at the 23rd International AIDS Conference (AIDS 2020: Virtual). For more podcasts like this, visit www.consultant360.com/infectious-diseases.